Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747654 | 0.79 | NPC1 (0.41) | NPC1TTRKMT2A | |
| SCHEMBL18823571 | 0.77 | NPC1 (0.71) | NPC1TTR | |
| SCHEMBL6751102 | 0.77 | NPC1 (0.84) | NPC1TTRKMT2A | |
| SCHEMBL14305454 | 0.76 | CYP11B1 (0.54) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL1762467 | 0.76 | CYP11B1 (0.54) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL4860547 | 0.74 | NPC1 (0.67) | NPC1TTR | |
| SCHEMBL1762224 | 0.72 | CES1 (0.57) | CYP11B1CYP11B2 | |
| SCHEMBL6906443 | 0.71 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP19A1KMT2A | |
| SCHEMBL6990481 | 0.70 | CYP11B1 (0.48) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL18823663 | 0.70 | DRD3 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | NPC1 2509/4885TTR 4604/4885CYP11B1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.